About the Company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AYLA News
IMNM Oct 2024 25.000 put
BOTHELL, Wash., February 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the ...
2024's 10 Best-Performing Stocks
Top 2024 stock market performers include health care stocks with unique catalysts, artificial intelligence stocks and a stock tied to former President Donald Trump. Here are the 10 best-performing ...
J&J Adds to 2024 M&A Upswing
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
"As sportsmen, we live on painkillers...pharmaceuticals have played role in terms of recovery": Javagal Srinath
Former India seamer Javagal Srinath has said that pharmaceuticals and multivitamins have played a role in terms of recovery ...
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals. Currently, the analyst consensus on ...
EyePoint Pharmaceuticals: Q4 Earnings Snapshot
WATERTOWN, Mass. (AP) — WATERTOWN, Mass. (AP) — EyePoint Pharmaceuticals (EYPT) on Thursday reported a loss of $14.1 million in its fourth quarter. On a per-share basis, the Watertown, ...
IMNM Oct 2024 25.000 call
BOTHELL, Wash., February 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the ...
Loading the latest forecasts...